• LAST PRICE
    10.8500
  • TODAY'S CHANGE (%)
    Trending Up0.1200 (1.1184%)
  • Bid / Lots
    10.8500/ 1
  • Ask / Lots
    10.8700/ 6
  • Open / Previous Close
    10.9400 / 10.7300
  • Day Range
    Low 10.6500
    High 11.2400
  • 52 Week Range
    Low 4.3400
    High 24.5500
  • Volume
    2,022,099
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 10.73
TimeVolumeVERU
09:32 ET12924911.05
09:34 ET5337410.86
09:36 ET4220210.82
09:38 ET3964010.78
09:39 ET5563010.8784
09:41 ET6522410.97
09:43 ET1299910.83
09:45 ET2149310.8299
09:48 ET2632110.83
09:50 ET2283910.9237
09:52 ET841610.9088
09:54 ET2531110.8
09:56 ET1144310.87
09:57 ET1138610.8657
09:59 ET678610.9037
10:01 ET1428310.86
10:03 ET2184010.86
10:06 ET1614710.9
10:08 ET1657710.81
10:10 ET1393210.84
10:12 ET474410.83
10:14 ET745410.8801
10:15 ET625910.9
10:17 ET1670010.9674
10:19 ET3129310.9785
10:21 ET1491711.055
10:24 ET4659911.13
10:26 ET1173311.12
10:28 ET2752010.99
10:30 ET743110.96
10:32 ET2307511.06
10:33 ET1185311.09
10:35 ET1608011.13
10:37 ET978111.11
10:39 ET1303411.08
10:42 ET865211.09
10:44 ET733611.1255
10:46 ET1196911.16
10:48 ET2386211.2299
10:50 ET1325811.16
10:51 ET621711.15
10:53 ET730211.16
10:55 ET1171911.18
10:57 ET3142611.2007
11:00 ET1659211.15
11:02 ET1003811.0899
11:04 ET565311.11
11:06 ET435611.11
11:08 ET222611.12
11:09 ET4514111.06
11:11 ET782011.06
11:13 ET695611.0012
11:15 ET1445510.99
11:18 ET599010.955
11:20 ET2017010.97
11:22 ET471110.96
11:24 ET1281210.945
11:26 ET180010.92
11:27 ET749210.91
11:29 ET1221610.88
11:31 ET1063810.895
11:33 ET1766310.86
11:36 ET947210.85
11:38 ET178410.855
11:40 ET840510.9184
11:42 ET390010.9388
11:44 ET1049910.93
11:45 ET255510.9
11:47 ET154110.865
11:49 ET643710.85
11:51 ET824210.85
11:54 ET1808910.835
11:56 ET379910.835
11:58 ET682110.8488
12:00 ET1396610.7831
12:02 ET852610.77
12:03 ET642410.76
12:05 ET984710.74
12:07 ET638510.72
12:09 ET1603210.74
12:12 ET1203210.73
12:14 ET6007410.6895
12:16 ET1934210.6808
12:18 ET828110.705
12:20 ET789910.665
12:21 ET730510.685
12:23 ET346410.695
12:25 ET136110.695
12:27 ET937210.7
12:30 ET202010.71
12:32 ET258210.7388
12:34 ET347010.73
12:36 ET2106210.81
12:38 ET2924310.715
12:39 ET1506510.7024
12:41 ET692710.72
12:43 ET190010.7
12:45 ET432010.705
12:48 ET437010.69
12:50 ET191210.72
12:52 ET300010.715
12:54 ET973510.68
12:56 ET134210.71
12:57 ET87710.7
12:59 ET835210.74
01:01 ET1449910.725
01:03 ET658010.75
01:06 ET464210.795
01:08 ET652310.8312
01:10 ET450010.82
01:12 ET569010.83
01:14 ET246510.85
01:15 ET370110.87
01:17 ET3390010.87
01:19 ET1511410.85
01:21 ET330010.84
01:24 ET545510.825
01:26 ET300110.8
01:28 ET467510.79
01:30 ET1779710.85
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVERU
Veru Inc
860.0M
-18.5x
+49.24%
United StatesUNICY
Unicharm Corp
20.0B
43.0x
+9.69%
United StatesSSDOY
Shiseido Co Ltd
13.8B
26.3x
+5.74%
United StatesTANH
Tantech Holdings Ltd
3.4M
-0.1x
---
United StatesPCGR
Personal Care Group Inc
780.0
0.0x
---
United StatesSLGD
Scotts Liquid Gold Inc
4.6M
-0.3x
---
As of 2022-09-27

Company Information

Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Contact Information

Headquarters
2916 N. MIAMI AVENUE, SUITE 1000MIAMI, FL, United States 33127
Phone
312-595-9123
Fax
312-595-9122

Executives

Chairman of the Board, President, Chief Executive Officer
Mitchell Steiner
Vice Chairman of the Board, Chief Corporate Officer
Harry Fisch
Chief Financial Officer, Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Barnette
Independent Director
Mario Eisenberger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$860.0M
Revenue (TTM)
$52.4M
Shares Outstanding
80.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.27
EPS
$-0.59
Book Value
$1.90
P/E Ratio
-18.5x
Price/Sales (TTM)
16.4
Price/Cash Flow (TTM)
---
Operating Margin
-77.12%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.